The European Patent Office published patent application EP3194596A1 on March 25, 2026, for complement component C5 IRNA compositions and methods of use thereof. The application designates all 34 European Patent Convention contracting states and is classified under C12N 15/113 and A61K 31/713. The patent was originally filed by Alnylam Pharmaceuticals, Inc. as applicant.

Pharmaceutical and biotech companies developing C5-targeting RNA interference therapeutics should review the patent claims for freedom-to-operate implications. Research institutions and drug developers working in complement pathway inhibition should assess whether their programs fall within the scope of the disclosed IRNA compositions and methods.